Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
In this 24-week, multi-center, randomized, double-blind study, the investigators will
evaluate the efficacy and safety profile of subcutaneously injected Yisaipu, a Tumor Necrosis
Factor Receptor Fusion Protein, combined with oral Tripterygium Wilfordii for patients with
active rheumatoid arthritis.